Skip to content
  • About ZoBio
  • Our Approach
  • Capabilities
  • Case studies
  • Events
  • News
  • Careers
  • Contact

News

7 September 2020

Mirati and ZoBio Collaborate to Advance Targeted Oncology Programs

Mirati Therapeutics has selected ZoBio to provide fragment-based screening, biophysical compound characterization and structural biology for several oncology targets. In this arrangement, ZoBio screens…

Read more
14 January 2020

Axxam and ZoBio Form a Strategic Alliance Integrating their Drug Discovery Services Platforms

MILAN, IT, AND LEIDEN, NL
Axxam and ZoBio have initiated a strategic alliance to provide a combination of integrated discovery services spanning all phases from gene to fully optimized leads.
This alliance provides access to a synergistic, industry-leading…

Read more
21 May 2019

Gotham Therapeutics and ZoBio Achieve Significant Milestone in Epitranscriptomic Drug Discovery Collaboration

NEW YORK, NY, USA AND LEIDEN, NL
Gotham Therapeutics has selected ZoBio to initiate a collaboration on the development of small molecules targeting epitranscriptomic targets. This collaboration has now resulted in several lead candidates for the METTL3/METTL14 complex…

Read more
« Previous 1 2

Search

In news only

By year

Latest news

Our tailor-made approach and tenacity will yield the right molecule for your target.

Contact us:

Privacy statement

ZoBio BV

J.H. Oortweg 19
2333 CH Leiden
The Netherlands
+31-71-2040580